IP Library Granted Patent US 9,599,623
Granted Patent B2
US 9,599,623 · App. 14/124,533 · Granted Mar 21, 2017

Diagnostic devices, methods and systems for detecting platelet factor 4 (PF4)/heparin antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,599,623
App. No.
14/124,533
Granted
Mar 21, 2017
Kind
B2
Abstract

The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (PF4)/heparin complex in a fluid sample. The assay utilizes an immobilized PF4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human PF4/heparin antibodies. Various devices, methods and systems based on the disclosed PF4/heparin assay are also provided.

Claims (22)

1. A device for detecting the presence of human platelet factor 4 (PF4)/heparin antibodies in a fluid sample, the device comprising:

a PF4/polyanion complex immobilized on a solid support and an anti-human antibody labeled with a non-particulate fluorescent dye in a lateral flow format, the labeled anti-human antibody being releasably attached to the solid support upstream of:

the immobilized PF4/polyanion complex; and

a fluid sample zone configured to receive the fluid sample;

wherein the solid support is a test strip comprising:

a conjugate pad comprising:

(i) a conjugate zone containing the labeled anti-human antibody;

(ii) the fluid sample zone, the fluid sample zone being positioned downstream of the conjugate zone; and

(iii) a sample buffer zone configured to receive a sample buffer that facilitates lateral transport of the fluid sample, the sample buffer zone being positioned intermediate to the conjugate zone and the sample zone; and

wherein the labeled anti-human antibody is contacted with the PF4/heparin antibodies in the fluid sample after the PF4/heparin antibodies have bound to the immobilized PF4/polyanion complex.

2. The device of claim 1 , wherein the non-particulate fluorescent label is an amine-reactive dye.

3. The device of claim 1 , wherein polyanion is selected from the group consisting of polyvinyl sulfonate, polystyrene sulfonate, polyanetholesulfonate, polyvinyl phosphate, polyvinyl phosphonate, polyvinyl sulfate, and a combination thereof.

4. The device of claim 3 , wherein the polyanion is polyvinyl sulfonate.

5. The device of claim 1 , wherein the labeled anti-human antibody is selected from the group consisting of: antibodies specific for IgG, IgA, IgM, and a combination thereof.

6. The device of claim 5 , wherein the labeled anti-human antibody comprises a combination of antibodies specific for IgG, IgA, IgM.

7. The device of claim 5 , wherein the labeled anti-human antibody comprises antibodies specific for IgG.

8. The device of claim 1 , wherein the labeled anti-human antibody is selected from the group consisting of: a goat antibody, a donkey antibody, a horse antibody, a sheep antibody, a rabbit antibody, a mouse antibody, a rat antibody, a llama antibody, a guinea pig antibody, a hamster antibody, a chicken antibody, and a combination thereof.

9. The device of claim 1 , wherein the conjugate pad further comprises a porous membrane positioned downstream of, and in fluid communication with the conjugate pad, the porous membrane comprising:

(i) a detection zone containing the PF4/polyanion complex immobilized thereon; and

(ii) a control zone containing a capture reagent immobilized thereon and configured to bind with the labeled anti-human antibody, the control zone being positioned downstream of the detection zone.

10. The device of claim 1 , wherein the conjugate pad further comprises a conjugate buffer zone configured to receive a conjugate buffer, the conjugate buffer zone being positioned upstream of the conjugate zone.

11. The device of claim 1 , wherein the test strip further comprises a wet pad containing a conjugate buffer zone configured to receive a conjugate buffer, the wet pad being positioned upstream of, and in fluid communication with, the conjugate pad.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0033 →
RELEASE OF SECURITY INTEREST Recorded Mar 15, 2023
From: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
To: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS, INC.
Reel/Frame 063090/0111 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0135 →
SECURITY INTEREST Recorded Jul 2, 2020
From: IMMUCOR, INC.; BIOARRAY SOLUTIONS LTD.; SIRONA GENOMICS, INC.; IMMUCOR GTI DIAGNOSTICS INC.
To: ALTER DOMUS (US) LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 053119/0152 →